The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Barclays Lifts FTSE's Lenders

Fri, 23rd Oct 2020 10:46

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - WINNERS

----------

Barclays up 6.2%. The lender kicked off the UK banking reporting season with a "resilient" performance in the third quarter of 2020. Barclays said pretax profit for the three months ended September came in at GBP1.15 billion, up sharply from GBP246 million a year earlier. Third-quarter group income declined 6% to GBP5.20 billion from GBP5.54 billion, however. Other FTSE 100 lenders rose in a positive read-across. StanChart climbed 4.7%, Lloyds was up 4.4%, HSBC rose 3.8% and NatWest was up 3.3%. They all report third-quarter results next week.

----------

FTSE 250 - LOSERS

----------

Airtel Africa down 4.5%. The Africa-focused mobile operator halved its interim dividend to 1.5 US cents from 3 cents a year earlier. Revenue in the first half of 2020 increased by 11% to USD1.82 billion from USD1.65 billion a year ago, with second-quarter revenue growth of 14%. Reported operating profit for the half year was USD472 million, up 20% year-on-year.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Pendragon, up 21%. The motor retailer is piling on more gains after surging 23% on Thursday. It had said Thursday that underlying pretax profit for the three months to ended September was GBP27.3 million, up sharply from GBP3.0 million from a year earlier.

----------

Goco Group up 6.3%. The price comparison site said revenue in the nine months ended September is up 13% annually at GBP130.5 million. Customers at its AutoSave Live arm have more than doubled to 597 from 241 a year earlier.

----------

Evgen Pharma, up 16%. The clinical stage drug development firm has landed all regulatory approvals for the STAR trial of its SFX-01 treatment. The drug is used to treat acute respiratory infections. Recruitment for the trial will begin at the end of October.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Avingtrans PLC, down 7.4%. Shareholder Nigel Wray sold 3.2 million shares in the company at 250 pence each, landing GBP8.1 million. Wray no longer has a stake in the company, which provides systems and services to the energy and industrial sectors.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
27 Jul 2018 13:14

Friday broker round-up

(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.

Read more
26 Jul 2018 12:54

Evgen Pharma Expects Final Results From Clinical Trials At End Of Year

LONDON (Alliance News) - Evgen Pharma PLC said Thursday it expects to receive the final read-out from two clinical trials by the end of 2018.The drug development company said at its annual

Read more
25 Jul 2018 14:48

Evgen concludes patient recruitment in STEM breast cancer trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer, it announced on Wednesday.

Read more
25 Jul 2018 13:57

Wednesday broker round-up

(Sharecast News) - Unite Group: Numis downgrades to hold with a target price of 900p.

Read more
25 Jul 2018 13:31

Evgen Pharma Metastatic Breast Cancer Trial Ends Patient Recruitment

LONDON (Alliance News) - Evgen Pharma PLC said Wednesday it has concluded its patient recruitment for its STEM Phase IIa trial of SFX-01 in metastatic breast cancer.Following the favourable

Read more
19 Jul 2018 16:21

UK Shareholder Meetings Calendar - Next 7 Days

Friday 20 JulyHomeserveKCOM GroupMonday 23 JulyEthernity Energy 24

Read more
13 Jun 2018 10:46

Evgen Pharma Annual Loss Narrows As It Continues Phase II Trials

LONDON (Alliance News) - Clinical drug development company Evgen Pharma PLC said Wednesday its annual loss narrowed in line with expectations.Evgen, which focuses on cancer and neurological

Read more
11 Jun 2018 11:33

Evgen STEM Interim Trial Result Show "Signs Of Anti-Tumour Activity"

LONDON (Alliance News) - Evgen Pharma PLC said Monday its STEM trial showed "early signs of anti-tumour activity" in breast cancer patients.STEM is the company's study of in a

Read more
2 May 2018 11:15

Evgen Pharma Gets European Patent For Sulforaphane Stablising Method

LONDON (Alliance News) - Drug development company Evgen Pharma said Wednesday that it has secured a European patent recognising its intellectual property for a method of stabilising sulforaphane,

Read more
20 Mar 2018 13:56

Evgen Pharma Begins Research Partnership With Imperial College London

LONDON (Alliance News) - Drug development company Evgen Pharma PLC has started a new research collaboration with Imperial College London focusing on SFX-01, the company's

Read more
13 Feb 2017 08:21

Evgen Pharma signs service agreement with drug development corsortium

(ShareCast News) - AIM-listed Evgen Pharma has signed a services agreement with a consortium of Cheshire-based drug developments firms for its sulforaphane product. APT Trans, the consortium of drug developers based in the Biohub at Alderley Park, which comprises of Aptus Clinical, Apconix and Seda

Read more
17 Jan 2017 12:35

Richard Moulson to join Evgen Pharma as CFO

(ShareCast News) - Clinical-stage drug development company Evgen Pharma announced the appointment of experienced healthcare executive Richard Moulson as its chief financial officer on Tuesday. The AIM-traded firm said Moulson was joining immediately as CFO-designate for a handover period to 28 Febru

Read more
11 Jan 2017 09:23

Evgen Pharma receives go ahead for haemorrhage drug trial

(ShareCast News) - Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has received a positive interim safety review from the independent Data Safety Monitoring Board (DSMB) for its Phase II double-blind placebo-controlled SAS trial

Read more
11 Jan 2017 09:17

Evgen Pharma Gets Positive Review For SFX-01 Phase II Study

Read more
17 Aug 2016 10:49

Evgen Pharma receives approval for breast cancer study

(ShareCast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that it has received a Clinical Trial Approval from the UK's regulatory agency for the commencement of its Phase II clinical trial of SFX-01 in breast cancer. The AIM-traded firm said patient recruitment w

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.